{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=24", "query": { "condition": "Solid Malignancy", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 5456, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T01:44:17.488Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03579446", "title": "Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Levorphanol", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Oxymorphone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-11-29", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579446" }, { "nct_id": "NCT03184870", "title": "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "BMS-813160", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2017-08-08", "completion_date": "2023-06-14", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184870" }, { "nct_id": "NCT00003597", "title": "Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant human thrombopoietin", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "1998-11", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 23, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003597" }, { "nct_id": "NCT07335497", "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced / Metastatic Solid Tumors" ], "interventions": [ { "name": "CR-001", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "trifluridine and tipiracil", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2026-02-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335497" }, { "nct_id": "NCT05450562", "title": "Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "SAR444200", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-09-20", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 4, "location_summary": "Los Angeles, California • New York, New York • Providence, Rhode Island + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450562" }, { "nct_id": "NCT01210846", "title": "A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "tivozanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-10", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2011-09-26", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Lafayette, Indiana + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01210846" }, { "nct_id": "NCT05103046", "title": "First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "UCT-03-008", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "1200 Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2021-12-23", "completion_date": "2025-12-15", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 5, "location_summary": "Los Angeles, California • Torrance, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103046" }, { "nct_id": "NCT03146962", "title": "High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Lung Cancer" ], "interventions": [ { "name": "Vitamin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2017-03-29", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 2, "location_summary": "Brooklyn, New York • New York, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03146962" }, { "nct_id": "NCT01407562", "title": "Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor - Protocol Specific", "Breast Cancer - Female" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-09-17", "completion_date": "2016-03-29", "has_results": false, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407562" }, { "nct_id": "NCT01476137", "title": "A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "GSK2110183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2011-10-26", "completion_date": "2013-03-12", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-25T01:44:17.488Z", "location_count": 2, "location_summary": "Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476137" } ] }